The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Updates in the Use of Liquid Biopsies for Multiple Tumor Types

Wafik El-Deiry, MD, PhD, FACP
Published Online:5:16 PM, Thu July 12, 2018


Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.

El-Deiry says some areas that are fairly new in the utility of liquid biopsies include more emphasis on early detection and diagnosis of disease. New issues have also been brought to light regarding clonal hematopoiesis, which can potentially give misleading results. This has led to debates in the oncology community on how to interpret results of liquid biopsies.

New information continues to enforce the value of liquid biopsy for disease monitoring, finding actionable targets, and resistance mechanisms, El-Deiry says.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.